Other languages Finch Therapeutics Group, Inc.

Equities

FNCH

US31773D2009

Delayed Nasdaq Other stock markets 11:09:14 2024-04-29 EDT			5-day change	1st Jan Change
2.33 ^USD	+0.43%		+0.87%	-35.46%

03-25	Finch Therapeutics Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-12	Top Premarket Decliners	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Finch Therapeutics Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-25
Top Premarket Decliners	03-12
Finch Therapeutics Group, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08
Finch Therapeutics Group, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Finch Therapeutics Group, Inc. Announces Resignation of Nicholas Haft as Member of Board	23-06-23
Top Premarket Decliners	23-06-13
Finch Therapeutics Group to Implement 1-for-30 Reverse Stock Split	23-06-09
Finch Therapeutics Group, Inc. Enters into Lease Termination Agreement with NRL WCS 200 Inner Belt Prop, LLC	23-05-18
Finch Therapeutics Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10
Finch Therapeutics Appoints Matthew Blischak CEO, Lance Thibault CFO	23-04-26
Finch Therapeutics Group, Inc. Announces Executive Leadership Transitions	23-04-25
Finch Therapeutics Group, Inc. Announces Executive Changes	23-04-25
Finch Therapeutics Reports Clinical Collaboration in Ulcerative Colitis; Shares Soar After-Hours	23-04-18
Finch Therapeutics Group, Inc. Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women's Hospital and Updates to University of Minnesota License Agreement	23-04-18
Finch Therapeutics Discontinuing Phase 3 Trial of Proposed Colon Infection Therapy, Slashing 95% of Staff	23-01-24
Finch Therapeutics Group, Inc. Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets	23-01-24
Finch Therapeutics Group, Inc. Announces Resignation of Joseph Vittiglio as Chief Business and Legal Officer and Secretary, Effective December 31, 2022	22-12-12
Finch Therapeutics Group, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10
Finch Therapeutics to Reduce Headcount by 37%, Shelves Phase 1 Trial of Autism Drug Candidate; Shares Fall Pre-Bell	22-09-01
Finch Therapeutics Group, Inc. Plans to Reduce its Workforce by Approximately 37%	22-09-01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Finch Therapeutics Group, Inc.

Equities

FNCH

US31773D2009

Other languages

Filters